Evidence map›Paper›PMID 42610503›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Programmable Paracrine-Mimetic Microneedle System for Temporal Regulation of Cardiac Repair.

Yichen Dai, Pengchong Du, Zhaoyang Wang, Surilige, Rangga Fokta, Renjian Tan, Xiqing Zhao, Shuoyi Zhang, Yuecheng Wang, Yixin Zhang and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yichen DaiSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Pengchong DuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China.ORCID https://orcid.org/0000-0002-9050-5007
Zhaoyang WangSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
SuriligeDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China.
Rangga FoktaSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Renjian TanSchool of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.
Xiqing ZhaoDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China.
Shuoyi ZhangSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Yuecheng WangSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Yixin ZhangSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Ziliang FuSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Rui GongSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.ORCID https://orcid.org/0009-0005-7448-3329
Cheng JiangSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.ORCID https://orcid.org/0000-0003-4386-0740
Yisheng HeSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.ORCID https://orcid.org/0000-0002-2217-6758
Qiguang WangCollege of Biomedical Engineering, Sichuan University, Chengdu, Sichuan, China.
Renke LiSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Khoon LimSchool of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-2486-196X
Junnan TangDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan, China.ORCID https://orcid.org/0000-0002-4340-5337
Xiaolin CuiSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.ORCID https://orcid.org/0000-0001-5118-0169

Funding

Australian Research Council DP250103558Australian Research Council FT230100249Henan Province Key R&D Program 241111313300Henan Provincial Clinical Medical Scientist Training Project HNCMS202418Key project at central government level: The ability establishment of sustainable use for valuable Chinese medicine resources 2060302Ministry of Science and Technology of China International Young Scholar Grant QN2023032004LNew South Wales Health H22/98586Shenzhen Natural Science FoundationThe Noncommunicable Chronic Diseases-National Science and Technology Major Project 2025ZD0547800
6 · The paper itself

Abstract

Dynamic paracrine signaling governs tissue repair, yet replicating this temporal complexity using acellular systems remains challenging. While recent advances include microcapped microneedle patches and the TIMED platform, these systems face limitations in customizability, release duration, and fabrication simplicity. Here, this study reports a programmable microneedle platform that mimics the temporal paracrine signaling logic of stem cell therapy by generating phase-biased, kinetically staggered, and partially overlapping availability of TGF-β, IGF-1, and VEGF through a tris(2,2'-bipyridyl)dichlororuthenium(II) hexahydrate/sodium persulfate (Ru/SPS)-modulated tyramine crosslinked hydrogel network. This system demonstrates enhanced advantages, including straightforward tunability of release kinetics via Ru/SPS concentration adjustment, extended release duration up to ∼60 days, and a simplified fabrication process. In myocardial infarction models, this stem cell-inspired temporal release promoted anti-inflammatory, anti-apoptotic, and pro-angiogenic responses, restoring ventricular function. Direct schedule-control experiments further showed that the tested TGF-β/IGF-1/VEGF program outperformed 7- and 28- day simultaneous-window delivery and two order-swapped 7/14/28-day programs across functional, structural, angiogenic, and cardiomyocyte-proliferation readouts. This strategy establishes a generalizable framework for engineering time-coded therapeutic materials that emulate biological signaling programs.

Indexed as

cardiac repairgrowth factorsmyocardial infarctionparacrine signaling

Identifiers

PMID42610503
PMCPMC13482941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.